Stay updated on Pembrolizumab Combo in Metastatic NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in Metastatic NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab Combo in Metastatic NSCLC Clinical Trial page
- CheckyesterdayChange DetectedThe webpage has undergone significant updates, including the addition of new facility names and locations, as well as a list of publications related to a clinical study. Notably, the MedlinePlus related topics have been expanded to include drug safety and counterfeit drugs.SummaryDifference21%
- Check8 days agoChange DetectedThe webpage has been updated with new dates for future events, specifically adding estimated last update dates in August 2025, while removing outdated dates from January 2022.SummaryDifference1.0%
- Check15 days agoChange DetectedThe web page has been updated from version v2.16.11 to v2.16.12.SummaryDifference0.1%
- Check23 days agoChange DetectedThe web page has been updated from version v2.16.10 to v2.16.11.SummaryDifference0.1%
- Check30 days agoChange DetectedThe page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.SummaryDifference0.9%
- Check37 days agoChange DetectedThe web page has updated its version from v2.16.6 to v2.16.8 and added a section on HHS Vulnerability Disclosure.SummaryDifference0.2%
Stay in the know with updates to Pembrolizumab Combo in Metastatic NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Metastatic NSCLC Clinical Trial page.